The Claim
Systemic mTORC1 inhibition with rapamycin prevents age-related declines in muscle mass, function, and neuromuscular junction integrity in 30-month-old male C57BL/6 mice, with effects differing across muscle types, including preservation in tibialis anterior, extensor digitorum longus, and triceps brachii but not in gastrocnemius, when treatment is initiated at 15 or 20 months of age.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Giving older mice a drug called rapamycin helps keep their muscles strong and working well as they age, especially in some muscles but not others.
See the scientific wording
Chronic mTORC1 inhibition with rapamycin preserves muscle mass, function, and neuromuscular junction integrity in aging mice, with effects varying by muscle type. In 30-month-old male C57BL/6 mice, rapamycin treatment starting at 15 or 20 months of age prevented age-related declines in grip strength, running distance, stride length, and energy expenditure. It preserved relative muscle mass in tibialis anterior, extensor digitorum longus, and triceps brachii, but not in gastrocnemius. These findings suggest that systemic mTORC1 suppression counteracts key features of sarcopenia in a muscle-specific manner.
What the research says
1 studyStudy: The neuromuscular junction is a focal point of mTORC1 signaling in sarcopenia
The study tested rapamycin in old mice and found it helped preserve muscle strength and structure, especially at the nerve-muscle connection, just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.